- Report
- October 2024
- 196 Pages
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- August 2025
- 199 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- July 2025
- 175 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- July 2025
- 175 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- November 2024
- 150 Pages
Global
From €5196EUR$5,950USD£4,514GBP
- Report
- April 2025
- 100 Pages
Global
From €5196EUR$5,950USD£4,514GBP
- Report
- April 2025
- 200 Pages
Global
From €2175EUR$2,490USD£1,889GBP
- Report
- April 2025
- 100 Pages
Global
From €5196EUR$5,950USD£4,514GBP
- Report
- August 2025
- 192 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- August 2025
- 180 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- August 2025
- 185 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- August 2025
- 189 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- May 2025
- 175 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- May 2025
- 175 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- April 2025
- 175 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- March 2025
- 317 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- September 2025
- 250 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- September 2025
- 250 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- September 2025
- 250 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- July 2025
- 175 Pages
Global
From €3921EUR$4,490USD£3,406GBP

Bisphosphonates are a class of drugs used to treat musculoskeletal disorders, such as osteoporosis, Paget's disease, and bone metastases. They work by inhibiting the activity of osteoclasts, the cells responsible for breaking down bone. Bisphosphonates are typically administered orally or intravenously, and are available in both generic and branded forms.
Bisphosphonates are widely used in the treatment of musculoskeletal disorders, and are often prescribed in combination with other drugs. They are generally well-tolerated, with few side effects. However, long-term use of bisphosphonates has been associated with an increased risk of atypical femur fractures.
The bisphosphonates market is highly competitive, with a number of major players. These include Merck & Co., Novartis, Amgen, Sanofi, and Pfizer. Other companies in the market include Eli Lilly, GlaxoSmithKline, and Teva Pharmaceuticals. Show Less Read more